Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Eur J Clin Chem Clin Biochem ; 34(7): 555-60, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8864404

ABSTRACT

Cathepsin D serum mass concentrations were determined by enzyme immunoassay in patients with hepatocellular carcinoma (n = 51) and/or liver cirrhosis (n = 92) or benign steatosis (n = 16) and correlated with some biochemical and clinical properties of these diseases. Increased cathepsin D serum mass concentrations (P < 0.001) were observed in all these groups of patients as compared to normal subjects (n = 98). However, patients with steatosis had serum mass concentrations of this enzyme significantly lower (mean 2-3 fold) than those measured in cancer patients (P < 0.05) or cirrhotic patients (P < 0.001). Interestingly, significantly higher cathepsin D serum mass concentrations (mean + 62%) (P < 0.006) were determined in the cirrhosis group as compared to cancer patients. No correlation between cathepsin D and a number of clinical and biochemical properties examined, namely, alpha-foetoprotein, number of neoplastic lesions and tumour size in cancer patients or, Child-Pugh grade of severity of cirrhosis and other enzymes of liver function tests in the cirrhotic group was found. The present data and those from other studies which indicate that cathepsin D may be involved in carcinogenesis suggest that this enzyme may be potentially useful as an additional biochemical marker to identify cirrhotic patients who may develop precancerous hepatic nodules.


Subject(s)
Carcinoma, Hepatocellular/enzymology , Cathepsin D/blood , Liver Cirrhosis/enzymology , Liver Neoplasms/enzymology , Adult , Aged , Female , Hepatitis, Alcoholic/enzymology , Humans , Immunoenzyme Techniques , Male , Middle Aged , alpha-Fetoproteins/analysis
2.
Anticancer Res ; 16(4B): 2315-9, 1996.
Article in English | MEDLINE | ID: mdl-8694562

ABSTRACT

Growing evidence indicates that lysosomal Cathepsins D (CD), B (CB) and L (CL) may promote carcinogenesis and tumor progression. Therefore, we evaluated their potential value as biochemical parameters of malignant progression in patients with benign diseases which may undergo malignant transformation, such as liver cirrhosis (LC) and chronic pancreatitis (CHP) as well as in hepatocellular carcinoma (HCC) and pancreatic cancer (DPC). CD, CB and CL serum levels were determined by immunoenzymatic assays in LC, CHP, HCC or DPC patients and correlated with a number of biochemical and clinical parameters of these diseases. CD serum levels were increased in LC, CHP and HCC, but not in the DPC group as compared to normal subjects (NS) (P < 0.01). Interestingly, higher levels of this enzyme were observed in LC patients compared to HCC patients ( P < 0.01). CB serum concentrations were increased in all patient groups (P < 0.01). However no difference was evidenced between benign and malignant diseases. CL serum levels were significantly increased only in DPC as compared to NS (P < 0.01) or CHP patients (P < 0.02) and in HCC as compared to NS (P < 0.01). The evaluation of CD, CB and CL serum pattern in LC, CHP, HCC and DPC patients may be useful as additional biochemical parameters in the differential diagnosis and therapeutic monitoring of these diseases. Prospective clinical investigations to assess the potential value of these enzymes as biochemical markers of malignant progression of LC or CHP are warranted by the present data.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Hepatocellular/diagnosis , Cathepsin B/blood , Cathepsin D/blood , Cathepsins/blood , Endopeptidases , Liver Neoplasms/diagnosis , Pancreatic Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Cathepsin L , Cysteine Endopeptidases , Female , Humans , Male , Middle Aged , Prognosis
3.
Minerva Gastroenterol Dietol ; 37(1): 29-33, 1991.
Article in Italian | MEDLINE | ID: mdl-1873327

ABSTRACT

The tolerance and the effect of ursodehoxycholic acid (UDCA) on the level of transaminases and gammaglutamyl-transpeptidase (GGT) has been estimated, over the short term, in 27 patients affected by compensated liver cirrhosis in comparison to 24 patients, representing the control group. The results were good with regard to GGT values, as a meaningful reduction was observed during the first month of therapy which then improved in the next five months. There was also a significant reduction in transaminase levels at the end of the second month of therapy, which was maintained until treatment was stopped; mean values however were not within the normal range. These results, together with tolerance of the drug confirm a role of UDCA in the treatment of chronic liver diseases in an advanced stage.


Subject(s)
Liver Diseases/drug therapy , Ursodeoxycholic Acid/therapeutic use , Aged , Chronic Disease , Female , Humans , Male , Middle Aged , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...